Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director · CHAIRMAN AND CEO | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 306,461 |
Ending reported balance
After 2026-08-25 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 151,869 · Balance 458,330 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 246,963 · Balance 705,293 Row 3 · 2026-08-25 · Sale · Disposed 218,535 · Balance 486,758 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2026-08-25 · Sale · Disposed 180,297 · Balance 306,461 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-25 · Exercise / conversion · Disposed 151,869 · Balance 0 F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-25 · Exercise / conversion · Disposed 246,963 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectFord Family Trust | 216,203 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 216,203 F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.
F4: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 246,963 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · derivative · entry 7 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 246,963 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 151,869 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · derivative · entry 6 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 151,869 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 180,297 | $116.19 | $20,948,708.43 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,461 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.36, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 218,535 | $115.57 | $25,256,089.95 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,758 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 246,963 | $59.94 | $14,802,962.22 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 151,869 | $44.40 | $6,742,983.60 |
DisclosureSEC source: 0001612571-26-000011 · form4-08272026_090838.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 00:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 30,308 | $116.26 | $3,523,608.08 |
DisclosureSEC source: 0001612571-26-000006 · form4-03042026_120340.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 306,461 Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 344,066 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001612571-26-000004 · form4-02262026_110221.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,066 Underlying: Common Shares · 344,066 shares Expires 2036-02-23 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,688 on February 24, 2027, 114,689 on February 24, 2028, and 114,689 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 83,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001612571-26-000004 · form4-02262026_110221.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,769 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 13:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | PurchaseCommon shares without par value | 18,800 | $107.13 | $2,013,966.92 |
DisclosureSEC source: 0001612571-26-000002 · form4-01262026_010121.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Ford Family Trust Disclosed balance after: 216,203 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.735 to $107.485, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 31,651 | $135.87 | $4,300,421.37 |
DisclosureSEC source: 0001415889-25-006755 · form4-03052025_120328.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,305 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 241,706 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005891 · form4-02272025_110246.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,706 Underlying: Common Shares · 241,706 shares Expires 2035-02-24 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 80,568 on February 25, 2026, 80,569 on February 25, 2027, and 80,569 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 64,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005891 · form4-02272025_110246.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,956 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 285,388 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · derivative · entry 4 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 285,388 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 285,388 | $131.17 | $37,435,200.12 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,059 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.68 to $131.38, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 22:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 285,388 | $38.40 | $10,958,899.20 |
DisclosureSEC source: 0001415889-25-003394 · form4-02072025_100204.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,243 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · derivative · entry 7 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 14,243 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 127,436 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · derivative · entry 6 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 127,436 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 61,380 | $116.90 | $7,175,322.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 4 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,059 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.58 to $117.29, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 80,299 | $116.04 | $9,317,895.96 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,439 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.58 to $116.54, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,243 | $48.90 | $696,482.70 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 127,436 | $47.00 | $5,989,492.00 |
DisclosureSEC source: 0001415889-24-023389 · form4-09132024_090935.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 31,610 | $120.05 | $3,794,780.50 |
DisclosureSEC source: 0001415889-24-006406 · form4-03042024_110304.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,059 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 264,293 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005088 · form4-02232024_100230.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,293 Underlying: Common Shares · 264,293 shares Expires 2034-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 88,097 on February 21, 2025, 88,098 on February 21, 2026, and 88,098 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 70,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005088 · form4-02232024_100230.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,669 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 30,742 | $99.77 | $3,067,129.34 |
DisclosureSEC source: 0001415889-23-003904 · form4-03032023_120329.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,337 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 276,082 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003051 · form4-02222023_110230.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,082 Underlying: Common Shares · 276,082 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 92,027 on February 17, 2024, 92,027 on February 17, 2025, and 92,028 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 70,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003051 · form4-02222023_110230.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,079 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 56,933 | $0.00 Strike: $41.14 | $0.00 |
DisclosureSEC source: 0001415889-22-009126 · form4-08262022_020808.xml · derivative · entry 6 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 56,933 shares Expires 2024-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 45,492 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001415889-22-009126 · form4-08262022_020808.xml · derivative · entry 5 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 45,492 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 102,425 | $105.10 | $10,765,154.29 |
DisclosureSEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,071 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.60 to $105.43, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 56,933 | $41.14 | $2,342,223.62 |
DisclosureSEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,496 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2022 Filed Aug 26, 2022 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 45,492 | $39.12 | $1,779,647.04 |
DisclosureSEC source: 0001415889-22-009126 · form4-08262022_020808.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2022 Filed Apr 1, 2022 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 33,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003603 · form4-04012022_020405.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 197,403 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| March 25, 2022 Filed Apr 1, 2022 21:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 33,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003603 · form4-04012022_020405.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,071 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:40 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,579 | $122.41 | $3,253,535.39 |
DisclosureSEC source: 0001415889-22-002191 · form4-03022022_040335.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,485 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 344,827 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001735 · form4-02232022_050220.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,827 Underlying: Common Shares · 344,827 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 114,942 on February 18, 2023, 114,942 on February 18, 2024, and 114,943 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 73,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001735 · form4-02232022_050220.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,064 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 25, 2021 Filed Jul 2, 2021 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 28,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003428 · form4-07022021_020723.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 163,989 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| June 25, 2021 Filed Jul 2, 2021 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 28,746 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003428 · form4-07022021_020723.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,072 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 22,865 | $121.58 | $2,779,926.70 |
DisclosureSEC source: 0001415889-21-001204 · form4-03022021_040308.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,818 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 359,090 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000891 · form4-02232021_030205.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,090 Underlying: Common Shares · 359,090 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 119,696 on February 19, 2022, 119,697 on February 19, 2023, and 119,697 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 70,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000891 · form4-02232021_030205.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,683 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| May 15, 2020 Filed May 22, 2020 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 20,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006504 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 135,243 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| May 15, 2020 Filed May 22, 2020 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 20,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006504 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,625 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 16,638 | $79.19 | $1,317,563.22 |
DisclosureSEC source: 0001179110-20-002919 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,543 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 390,896 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002275 · edgar.xml · derivative · entry 3 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,896 Underlying: Common shares · 390,896 shares Expires 2030-02-20 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 130,298 on February 21, 2021, 130,299 on February 21, 2022, and 130,299 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 64,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002275 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,181 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 18,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007400 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 114,325 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 18,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007400 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,057 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.